Sign In
Buy FBIOP
$6.69
-0.309 (-4.42%)
At Close: Nov 17, 2025
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
08:30am, Friday, 14'th Nov 2025
Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received
Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript
10:41pm, Wednesday, 12'th Nov 2025
Fortress Biotech, Inc. ( FBIO ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Jaclyn Jaffe - Senior Director of Corporate Operations Claude Maraoui - Founder, President, CEO
Fortress Biotech (NASDAQ:FBIOP) Stock Price Down 1.9% – Time to Sell?
02:49am, Tuesday, 04'th Nov 2025
Fortress Biotech, Inc. (NASDAQ: FBIOP - Get Free Report)'s share price was down 1.9% during mid-day trading on Monday. The stock traded as low as $6.80 and last traded at $6.87. Approximately 7,918 sh
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystaly
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing
08:05am, Wednesday, 01'st Oct 2025
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
08:00am, Wednesday, 01'st Oct 2025
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
08:30am, Tuesday, 02'nd Sep 2025
MIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
04:05pm, Thursday, 14'th Aug 2025
Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
10:47am, Friday, 30'th May 2025
Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™ (c
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
04:05pm, Thursday, 15'th May 2025
Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkp
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
08:00am, Wednesday, 07'th May 2025
MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term v
Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript
07:39pm, Wednesday, 26'th Mar 2025
Fortress Biotech, Inc. (NASDAQ:FBIO ) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder,
FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strate
Study is the first randomized, controlled trial examining a vaccine's effectiveness in controlling CMV in recipients of HSCT from vaccinated donors
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones C
